A Portrait of SARS-CoV-2 Infection in Patients Undergoing Hematopoietic Cell Transplantation: A Systematic Review of the Literature.
A Portrait of SARS-CoV-2 Infection in Patients Undergoing Hematopoietic Cell Transplantation: A Systematic Review of the Literature.
复制标题
DOI：
10.3390/curroncol29010030
复制
发表时间：
2022-01-13
期刊：
影响因子：
--
通讯作者：
Allan DS
中科院分区：
文献类型：
--
作者：
Bailey AJM;Kirkham AM;Monaghan M;Shorr R;Buchan CA;Bredeson C;Allan DS
造血细胞移植（HCT）受者的COVID-19管理是一项特殊的挑战，因为该人群的免疫失调状态多变，疫苗效力也发生了变化。需要进行系统检索（奥维德Medline和Embase，2021年6月1日），以更好地了解表现特征、预后因素和治疗选择。在897条记录中，我们检索了29项研究。大多数报告成人和儿童接受者的研究描述了COVID-19的典型体征和症状。总体而言，死亡率很高，21%的成人和6%的儿童HCT接受者死于COVID-19。据报告与死亡率增加有关的因素包括年龄（HR = 1.21，95% CI 1.03-1.43，p = 0.02），入住ICU（对于同种异体和自体HCT接受者，HR = 4.42，95%CI 2.25-8.65，p < 0.001和HR = 2.26，95%CI 1.22-4.20，p = 0.01）和低血小板计数（OR = 21.37，95% CI 1.71-267.11，p = 0.01）。体力状态与死亡率降低相关（HR = 0.83，95% CI 0.74-0.93，p = 0.001）。描述了广泛的治疗方法，但未确定对照研究。使用Newcastle-Ottawa量表，偏倚风险较低。接受HCT的患者面临与COVID-19相关的严重发病率和死亡率的高风险。需要对潜在治疗进行对照研究，以确定该人群的疗效和安全性。
The management of COVID-19 in hematopoietic cell transplant (HCT) recipients represents a special challenge given the variable states of immune dysregulation and altered vaccine efficacy in this population. A systematic search (Ovid Medline and Embase on 1 June 2021) was needed to better understand the presenting features, prognostic factors, and treatment options. Of 897 records, 29 studies were identified in our search. Most studies reporting on adults and pediatric recipients described signs and symptoms that were typical of COVID-19. Overall, the mortality rates were high, with 21% of adults and 6% of pediatric HCT recipients succumbing to COVID-19. The factors reported to be associated with increased mortality included age (HR = 1.21, 95% CI 1.03–1.43, p = 0.02), ICU admission (HR = 4.42, 95% CI 2.25–8.65, p < 0.001 and HR = 2.26, 95% CI 1.22–4.20, p = 0.01 for allogeneic and autologous HCT recipients), and low platelet count (OR = 21.37, 95% CI 1.71–267.11, p = 0.01). Performance status was associated with decreased mortality (HR = 0.83, 95% CI 0.74–0.93, p = 0.001). A broad range of treatments was described, although no controlled studies were identified. The risk of bias, using the Newcastle–Ottawa scale, was low. Patients undergoing HCT are at a high risk of severe morbidity and mortality associated with COVID-19. Controlled studies investigating potential treatments are required to determine the efficacy and safety in this population.
登录
查看更多内容
影响因子：
4.8
作者：
El Fakih R;Haroon A;Alfraih F;Al-Khabori MK;Alzahrani M;Alhuraiji A;Hamadah A;AlJohani NI;Alahmari B;Essa MF;Motabi IH;Tailor IK;Almaghrabi RS;Al-Farsi K;Abosoudah I;Ayas M;Elhassan TA;Suhebeh AM;Ahmed SO;Alhayli S;Kaloyannidis P;Alsaeed A;Anezi KA;Alamoudi S;Damlaj M;Hashmi HA;Aljurf M
通讯作者：
Aljurf M
影响因子：
4.1
作者：
Garcia-Salido, Alberto;Leoz-Gordillo, Ines;Serrano-Gonzalez, Ana
通讯作者：
Serrano-Gonzalez, Ana
影响因子：
158.5
作者：
Cavalcanti, A. B.;Zampieri, F. G.;Berwanger, O.
通讯作者：
Berwanger, O.
影响因子：
11.4
作者：
Ljungman P;de la Camara R;Mikulska M;Tridello G;Aguado B;Zahrani MA;Apperley J;Berceanu A;Bofarull RM;Calbacho M;Ciceri F;Lopez-Corral L;Crippa C;Fox ML;Grassi A;Jimenez MJ;Demir SK;Kwon M;Llamas CV;Lorenzo JLL;Mielke S;Orchard K;Porras RP;Vallisa D;Xhaard A;Knelange NS;Cedillo A;Kröger N;Piñana JL;Styczynski J
通讯作者：
Styczynski J
影响因子：
2.8
作者：
Bouchlaka MN;Redelman D;Murphy WJ
通讯作者：
Murphy WJ